Revealing Hidden Nodal Disease: FDG PET/CT Driven Detection of Occult Lymph Node Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Clin Nucl MedApr 16, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)

Nivedita Kundu, Jagatti Krishna, Rakesh Kumar et al.

✦ AI-curated · Sources linked

Case in brief

A 32-year-old man presented with multiple violaceous cutaneous nodules and underwent F-18 FDG PET/CT for staging. The imaging revealed extensive metabolic activity in the skin and previously undetected inguinal and cervical lymph node involvement. Histopathological examination confirmed the diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The case underscores the importance of PET/CT in accurately staging this aggressive malignancy.

Diagnostic / clinical pearl

FDG PET/CT is essential for detecting occult lymph node involvement in blastic plasmacytoid dendritic cell neoplasm, enhancing staging accuracy and guiding management.

Source

PubMed · PMID 42029091

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.